The great variability of the effects of topically applied antibiotic and chemotherapeutic drugs to the central nervous system is not generally appreciated, in spite of numerous clinical and experimental studies. Many of these drugs are epileptogenic. Others are severe cortical "depressants," and still others have no significant effect on the electrical activity or histological appearance of the central nervous system. To keep up with the rapid development of new antibacterial agents, Hanbery and Ajmone-Marsan 1 in 1954 investigated the effects on the central nervous system of chloramphenicol, penicillin, streptomycin, bacitracin, neomycin, erythromycin, chlortetracycline (Aureomycin), oxytetracycline (Terramycin), and polymyxin B. Before this, Russell and Falconer, 2 Jasper et al, 3 and Botterell et al 4 investigated the effects of various sulfonamides on the brain; Walker et al 5,6 investigated the effects of penicillin on the cortex; and Teng et al 7,8 studied bacitracin. Newer drugs are coming on the market all

01 Jan 1960·A.M.A. Journal of Diseases of Children

Report of an Unusual Case with a Communicating Congenital Dermal Sinus and Recurrent Meningitis

Article

Author: FISHER, DELBERT A.

A case is reported which manifests recurrent, resistant meningitis with an intraspinal embryonal rest tumor and a communicating ventral sinus tract. A review of the literature has disclosed no similar case. Report of Case This white girl was admitted to the University Hospital at the age of 15 months. She was the product of the second uneventful pregnancy and delivery of a 23-year-old healthy mother. Family history was unrevealing. Growth and development were essentially normal until the age of 9 months when the child contracted purulent meningitis. Klebsiella and paracolon bacilli were cultured and found to be sensitive to oxytetracycline (Terramycin) and chloramphenicol (Chloromycetin); after a two weeks' course of these antibiotics, recovery was apparently complete and spinal fluid normal. A second episode of purulent meningitis occurred at the age of 11 months. Cultures showed no growth. Treatment with sulfonamides, penicillin, and chloramphenicol was followed by clinical and spinal fluid

100 Deals associated with Oxytetracycline Hydrochloride/Polymyxin B Sulfate

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Burns	Japan	Yoshindo, Inc.	31 May 1956
Pyoderma	Japan	Yoshindo, Inc.	31 May 1956
Secondary infection	Japan	Yoshindo, Inc.	31 May 1956
Skin and skin structure infections	Japan	Yoshindo, Inc.	31 May 1956

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Oxytetracycline Hydrochloride/Polymyxin B Sulfate

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation